EUGENE HUANG, M. D.
BOARD CERTIFIED RADIATION ONCOLOGIST
Dr. Huang is the full-time physician at Southeast Radiation Oncology.
Dr. Huang attended Baylor College of Medicine, and received his oncology training at the M.D. Anderson Cancer Center, the number one ranked cancer hospital in the world. He formerly practiced at the Cleveland Clinic.
Dr. Huang serves as a scientific peer reviewer for several leading medical journals, including the International Journal of Radiation Oncology, Biology, Physics, and Breast Diseases Quarterly. He has received numerous awards for outstanding scientific research in breast and prostate cancer, including: the RSNA Roentgen Fellow Research Award, the Gilbert Fletcher Research Award, and the James Alexander Symposium.
Dr. Huang has been invited to present his research at numerous international conferences for prostate, breast, and lung cancer, including the American Association for Cancer Research, the American Society of Clinical Oncology, the American Society for Radiation Oncology, and the American Radium Society.
Dr. Eugene Huang has over 40 original scientific publications.
The first paper ever that studied postmastectomy radiation after neoadjuvant chemotherapy, and its findings have since been utilized to establish national cancer care guidelines.
Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 2004 Dec 1;22(23):4691-4699.
Comparing risk of recurrence after breast conservation therapy versus mastectomy.
Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Intl J Radiat Oncol Biol Phys 2006 Oct 1;66(2):352-7.
Outcomes for breast cancer patients with supraclavicular nodal disease.
Locoregional treatment outcomes for patients with ipsilateral supraclavicular metastases at diagnosis of breast cancer. Intl J Radiat Oncol Biol Phys 2007 Feb 1;67(2):490-6.
Predictors of local-regional recurrence.
Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiation. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):351-357.
Classifying recurrences as new primary tumors versus true recurrences.
Classifying local disease recurrences after breast conserving therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer. 2002 Nov 15;95(10):2059-67.
Radiation for inoperable breast cancers
Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1225-33.
The effect of metallic ports in breast tissue expanders.
The Impact of Internal Metallic Ports within Temporary Tissue Expanders on Postmastectomy Radiation Dose Distribution. Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):630-635
Outcomes for young women with breast cancer.
Effect of Postmastectomy radiation therapy in stage II-III breast cancer <35 years old treated with doxorubicin based neoadjuvant chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys 2007 Dec 1;69(5):1478-83.
Radiation reduces distant metastases even after a complete response to chemotherapy.
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 2005 Oct 1;23(28):7098-7104.
Radiation reduces local recurrences even after a complete response to chemotherapy.
Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1004-9.
African-American race is associated with poorer outcomes.
African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy. Cancer 2006 Dec 1;107(11):2662-8.
Outcomes of Her-2-neu receptor positive disease.
HER2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiation. Int J Radiat Oncol Biol Phys. 2004 59(5):1337-1342.
The initial publication of the landmark M.D. Anderson Cancer Center randomized phase III dose escalation trial that changed the standard of care worldwide for patients with prostate cancer.
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105.
The updated long-term results of the M.D. Anderson dose escalation trial.
Long-term results of the M. D. Anderson randomized dose escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008 Jan 1;70(1):67-74.
The publication that established the dose-volume parameters that are now currently used for quality-assurance everyday for all prostate cancer patients treated with radiation.
Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1314-21.
The potential hazards of dose escalation in prostate cancer.
Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1260-8.
One of the very first studies that analyzed the effect of prostate motion during each radiation treatment.
Intrafraction prostate motion during IMRT for prostate cancer. Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):261-8.
The very first publication that lead to the widespread adoption of using ultrasound everyday to track prostate motion.
Experience of ultrasound-based daily prostate localization. Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):436-447.
The first study that showed the advantages of IMRT radiation to reduce side effects.
Late gastrointestinal and genitourinary toxicity following intensity modulated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2001, Nov 1; 51(3) Suppl.1:310-311.
Characterizing the probability of normal tissue complications.
Characterization of rectal normal tissue complication probability after high-dose external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Apr 58(5):1513-1519.
Analysis of dose-volume effects on rectal toxicity.
Dose-volume response analyses of late rectal bleeding after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):353-365.
Analysis of rectal modeling on toxicity.
Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy. Int J Radiat Oncol Biol Phys 2004 Dec 1;60(5):1589-1601.
Interesting case study #1
Recurrence of prostate adenocarcinoma presenting with multiple myeloma simulating skeletal metastases of prostate adenocarcinoma. Urology. 2002 Dec;60(6):1111.
Interesting case study #2
Prostate adenocarcinoma presenting with inguinal lymphadenopathy. Urology. 2003 Feb;61(2):463.
One of the very first studies to demonstrate the benefits of induction and concurrent chemotherapy with radiation for lung cancer.
Comparison of outcomes for patients with unresectable locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone. Intl J Radiat Oncol Biol Phys 2007 Jul 1;68(3):779-85.
Differences in outcomes between women and men with lung cancer. Gender differences in NSCLC outcomes. Intl J Radiat Oncol Biol Phys 2007 Supp. Vol 69, No 3.
Brain and Head-neck Cancer
The very first publication ever to demonstrate a direct clinical benefit of the new radiation technology IMRT by reducing hearing loss in pediatric brain tumors. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Intl J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):599-605.
IMRT technology to reduce xerostomia.
Dosimetric predictors of xerostomia for head and neck cancer patients treated with the SMART (simultaneous modulated accelerated radiation therapy) boost technique. Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):136-44.
Correlation of xerostomia symptoms and dosimetric factors.
SMART (simultaneous modulated accelerated radiation therapy) boost technique: correlation of subjective xerostomia and dosimetric parameters of the parotid glands. Int J Radiat Oncol Biol Phys 2002 Oct 1;54(2) Suppl.1:18-19.
IMRT technology to deliver a simultaneous boost to reduce treatment times and improve outcomes.
Accelerated fractionation for head and neck cancer using the SMART boost technique. Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3)Suppl.1:179-180.